Life Sciences

New businesses, new markets

It has been another challenging year for the global life science industry. Economic crisis in Europe, pricing pressures, reputational hits, and a perceived lack of transparency in clinical trial reporting are just a few. Yet opportunities for the industry abound–in the fast emerging markets beyond the BRICs, personalized medicine, and in harnessing ‘the power of networks’ to transform R & D. How will the industry rise to the challenge?

The Financial Times 2013 Pharmaceutical & Biotechnology Conference

On 3-4 December 2013, over 200 life sciences executives will gather in London to discuss today's pressing industry issues at the FT Pharma/Biotech Conference. Listen to our podcast as Pete Mooney, DTTL Global Life Sciences (LSHC) Industry Leader; and Mike Standing, DTT European Regional LSHC Industry Leader, discuss several of the topics and on the conference agenda and share their perspectives on the future direction of the industry.

Did you find this useful?